Our Québec City and Montréal offices advised OpSens Inc., a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, in connection with the sale of all of its issued and outstanding shares to Haemonetics Corporation, a global medical technology company, for C$2.90 in cash per share. The transaction was effected by way of a statutory plan of arrangement under the Business Corporations Act (Québec).

We provided strategic and legal advice to OpSens and its special committee of independent directors throughout the process that led to this going-private transaction. We have supported and advised OpSens historically through to this critical moment. In addition to providing key securities law and other legal advice to OpSens throughout the transaction, we assisted OpSens in evaluating and negotiating the key terms of this transaction which resulted in a purchase price of C$2.90 in cash per share, representing a premium of approximately 50% to the closing price of its shares on the TSX on the day prior to announcement. 

OpSens Inc. leadership commented:

“We could not have asked for a better strategic and legal partner than Norton Rose Fulbright, both historically and in the context in this critical transaction. Norton Rose Fulbright’s teams skillfully guided us through the intricacies of being a growing medical device company and successfully navigated us to the closing of this transaction,” said Louis Laflamme, President and Chief Executive Officer of OpSens. “The Norton Rose Fulbright team demonstrated impressive expertise and tenacity and an ability to be nimble and practical, giving us the utmost confidence and comfort in each and every one of their team members throughout this complex and challenging process.”

Practice areas:

Industries: